Activation of PPARγ by thiazolidinediones, high-affinity agonists for PPARγ, lowers arterial pressure and exerts vasoprotective effects in patients with type 2 diabetes enrolled in the PROactive trial of pioglitazone (25). The gene discussed is PPARG; the disease is type 2 diabetes mellitus.